id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-312918-iof45k1r	Ortolani, Claudio	Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?	2020-09-09		.txt	text/plain	4637	213	45	Recently, four large Randomized Controlled Trials (RCTs) have been performed in record time delivering reliable data: (1) the National Institutes of Health (NIH) RCT included 60 hospitals participating all over the world and showed the efficacy of remdesivir in reducing the recovery time in hospitalized adults with COVID-19 pneumonia; (2) three large RCTs already completed, for hydroxychloroquine, dexamethasone and Lopinavir and Ritonavir respectively. In 2019, at the beginning of the SARS-CoV-2 pandemic, at least 4 anti-inflammatory and antiviral drugs were available and in use, with possible efficacy for COVID-19: hydroxychloroquine, corticosteroids, remdesivir and Lopinavir / Ritonavir. Remark 1 cited a number of systematic reviews, which however had selected only observational clinical studies that addressed the efficacy and side effects of the corticosteroid treatment of viral pneumonia from SARS, H1N1 influenza virus and MERS virus, but not from SARS-CoV-2 virus [31] [32] [33] [34] .	./cache/cord-312918-iof45k1r.txt	./txt/cord-312918-iof45k1r.txt